Phase 2 N=28 Testosterone and Myocardial Perfusion in Coronary Heart Disease (CHD)
Coronary Heart Disease
Primary: Myocardial Perfusion — 1.83; 1.52 myocardial perfusion index
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=140 Clinical Effects of Eptifibatide Administration in High Risk Patients Presenting With Non-ST Segment Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Urgent Coronary Artery Bypass Graft Surgery in Short- and Long-Term Follow-up
Non ST Elevation Myocardial Infarction
Primary: Major Adverse Cardiac and Cerebrovascular Events (MACCE) — 35.3; 13.8 Percentage of study group
N/A N=34 Assessing the Hemodynamic Benefits of Cardiac Resynchronization Therapy in Children Following Open-Heart Surgery
Congenital Heart Defects
Primary: Cardiac Index — 3.39; 3.42; 3.23 L/min/m2
N/A N=45 Coronary Heart Disease as Measured by Coronary Calcium Score Among Individuals With Chronic Traumatic Spinal Cord Injury
Spinal Cord Injuries · Heart Diseases
Primary: Percent Agreement Between Coronary Calcium Score (CCS) and National Cholesterol Education Program (NCEP) Guidelines — 18 percent agreement
Phase 2 N=20 Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI
Myocardial Ischemia
Primary: Quantification of Myocardial Blood Volume — 3.63; 1.23 seconds^-1
Phase 3 N=22 Coronary Artery Vasculopathy in Pediatric Heart Transplant Patients
Orthotopic Heart Transplant
Primary: Coronary Flow Reserve (CFR) — 1.77 ratio: peak to baseline CFV
Phase 4 N=24 Atrial Fibrillation Without Hemodynamic Instability in the Intensive Care Unit
Atrial Fibrillation
Primary: Conversion From Atrial Fibrillation to Sinus Rhythm — 8; 5 participants
N/A N=105 Oxford Acute Myocardial Infarction - Pressure-controlled Intermittent Coronary Sinus Occlusion
ST Elevation Myocardial Infarction
Primary: Index of Microcirculatory Resistance — 24.8; 45.0 units
N/A N=371 Dynamic Coronary Roadmap for Contrast Reduction
Coronary Artery Disease
Primary: Total Percutaneous Coronary Intervention (PCI) Iodinated Contrast Volume — 64.6; 90.8 ml
N/A N=200 Hybrid Coronary Revascularization Trial
Coronary Artery Disease
Primary: Major Adverse Coronary and Cerebrovascular Events (MACCE) — 0.130; 0.111 MACCE Event Rate per Person-Year
Phase 4 N=43 Effect of Pioglitazone on Insulin Resistance, Atherosclerosis Progression and Clinical Course of Coronary Heart Disease
Adverse Effect · Atherosclerosis, Coronary · Insulin Resistance Syndrome
Primary: Сardiovascular Death — 0; 0; 0; 0 Participants
N/A N=223 SYNTAX III REVOLUTION Trial: A Randomized Study Investigating the Use of CT Scan and Angiography of the Heart to Help the Doctors Decide Which Method is the Best to Improve Blood Supply to the Heart in Patients With Complex Coronary Artery Disease
Coronary Artery Diseases · Multivessel Coronary Artery Disease · Heart Diseases
Primary: Inter-rater Agreement on Revascularization Strategy of Two Heart Teams Using an "Angio-first" Algorithm or a "CT First" Algorithm. — 0.82 proportion of agreement
N/A N=5,179 International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)
Cardiovascular Diseases · Coronary Disease · Coronary Artery Disease
Primary: Primary Composite Outcome: Death From Cardiovascular Causes, Myocardial Infarction, or Hospitalization for Unstable Angina, Heart Failure, or Resuscitated Cardiac Arrest…
Phase 4 N=100 The Effect of IV Cangrelor and Oral Ticagrelor Study
Acute Coronary Syndrome (ACS) · High On-treatment Platelet Reactivity (HTPR) · Microvascular Obstruction (MVO)
Primary: Degree of Platelet Inhibition Measured — 248.3; 145.2 Platelet Reactivity Units (PRU)
N/A N=130 A Comparative Study of Different Treadmill Scores to Diagnose Coronary Artery Disease
Stable Ischemic Heart Disease
Primary: Exercise Treadmill Scores — 0.771; 0.772; 0.768 Probability by AUC